At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid Arthritis
In Brief
An observational study evaluating tofacitinib, tumor necrosis factor inhibitors (TNFi), and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 21,340 participants across 1 site.
Detailed Summary
The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling. The study will look at data from a large, US-based group of RA patients who have taken the below medicines: * Tofacitinib * Abatacept * Tocilizumab or sarilumab The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.
Study Details
Timeline
Interventions
New index treatment of tofacitinib
New index treatment of TNFi
New index treatment of abatacept
New index treatment of tocilizumab or sarilumab